BMAC – Biopharmaceutical Manufacturer's Advisory Council
An initiative by leading Biopharmaceutical companies in the world to establish Singapore as the country of choice for global biomedical sciences manufacturing.
Our R&D engine has produced exciting new molecular entities (NMEs) across our core Therapeutic Areas: Oncology, Rare Genetic and Hematology, Neuroscience and Gastroenterology. In these areas, we’re focused on targeted patient populations where we’re able to deliver the greatest therapeutic benefit for patients.
Our pipeline is projected to deliver value in two distinct waves. In the near-term through FY2024, there are 12 NMEs with the potential for 15 launches, representing best-in-class or first-in-class therapies.
At Takeda Singapore Manufacturing site, the Training Dept has AR (Augmented Reality) for an immersive training experience to enhance our people’s capability.
Takeda has made environmental efforts and its commitment to carbon zero by 2040 a priority.